Evidence map›Paper›PMID 39554379›Full record

ArticleGynecologic oncology reports2024

Sleep characteristics and recurrence in platinum-sensitive ovarian cancer survivors: A prospective cohort study.

Mélanie Benoit, Marie-Pierre Sylvestre, Geetanjali Datta, Lucy Gilbert, Vikki Ho, Igor Karp, Julie Lacaille, Susie Lau, Vanessa Samouëlian, Anita Koushik

Abstract read
In one paragraph

Article in Gynecologic oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mélanie BenoitUniversité de Montréal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.
Marie-Pierre SylvestreUniversité de Montréal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.
Geetanjali DattaCedars Sinai, Los Angeles, CA, USA.
Lucy GilbertDivision of Gynecologic Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
Vikki HoUniversité de Montréal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.
Igor KarpDepartment of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.
Julie LacailleUniversité de Montréal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.
Susie LauGynecologic Oncology and Colposcopy, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada.
Vanessa SamouëlianUniversité de Montréal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.
Anita KoushikUniversité de Montréal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To describe characteristics of sleep (quality, duration, efficiency, and insomnia) in a cohort of high-grade epithelial ovarian cancer (EOC) survivors who have completed and responded to first-line chemotherapy, and to explore their relationships with disease recurrence. Methods: In this cohort of 97 women, sleep and other factors were assessed at baseline and 4 months later. The distribution of participants by categories of sleep characteristics were calculated. Hazard ratios (HRs) and 95 % confidence intervals (95 % CI) for the association between each sleep characteristic and recurrence were estimated using the Cox proportional hazards model, and adjusted for confounding using propensity scores. Associations were estimated for all women and among those defined as fully platinum-sensitive. Results: At baseline, just over half of participants (52.6 % to 56.7 %) had poor sleep quality, efficiency and duration, while most (62.9 %) did not experience insomnia. Distributions remained similar 4 months later. During follow-up, 47 recurrences occurred. Among all participants, HRs (95 % CIs) of recurrence were close to the value of 1, indicating no association, for sleep quality and efficiency, 1.22 (0.66-2.23) for not meeting vs. meeting sleep duration guidelines and 0.68 (0.34-1.39) for the presence vs. absence of insomnia. In fully platinum-sensitive women, the HRs (95 % CIs) were 1.50 (0.64-3.53) for not meeting duration guidelines, 1.25 (0.56-2.79) for poor sleep efficiency, 1.44 (0.55-3.72) for the presence of insomnia, and remained null for sleep quality. Conclusion: Most EOC survivors have poor sleep quality, duration, and efficiency. Research with larger sample sizes is required to better understand the relationship between these sleep characteristics and the risk of recurrence.

Indexed as

ISIOvarian CancerPrognosisPSQIRecurrenceSleep

Identifiers

PMID39554379
PMCPMC11567917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.